0001293971-24-000022.txt : 20240711 0001293971-24-000022.hdr.sgml : 20240711 20240711073842 ACCESSION NUMBER: 0001293971-24-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240709 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240711 DATE AS OF CHANGE: 20240711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 241111044 BUSINESS ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 8-K 1 blue-20240709.htm 8-K blue-20240709
0001293971FALSE00012939712024-07-092024-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________
FORM 8-K
__________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 9, 2024
__________________________
bluebird bio, Inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________________________
Delaware
001-35966
13-3680878
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
455 Grand Union Boulevard,
Somerville, MA
02145
(Address of Principal Executive Offices)(Zip Code)
(339) 499-9300
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per shareBLUEThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 




Item 1.01
Entry into a Material Definitive Agreement.

On July 9, 2024, bluebird bio, Inc. (the “Company”) entered into an amendment (the “Second Amendment”) to its Loan and Security Agreement (the “LSA”), dated as of March 15, 2024, as amended on April 30, 2024, by and among the Company, the several banks and other financial institutions or entities party thereto, as lenders (collectively, the Lenders”), and Hercules Capital, Inc., as administrative agent and collateral agent (the “Agent”).

Pursuant to the Second Amendment, the Company, the Agent and the Lenders agreed to, among other things: (i) extension of the period during which the Company will provide revised monthly financial reporting metrics to the Lenders; and (ii) extension of the deadlines by which the Company must provide to the Lenders financial statements for the year ended December 31, 2023 and for each of the quarters ended March 31, 2024 and June 30, 2024. Further, the Second Amendment provides that the Company’s late delivery and filing of its Form 10-K for the year ended December 31, 2023 and Forms 10-Q for the quarters ended March 31, 2024 and June 30, 2024 shall not be deemed a violation of the Company’s covenant to maintain compliance with applicable law, so long as such documents are filed by the extended deadlines.

The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by the full text of the Second Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Forward-Looking Statements

This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s expectations with respect to the filing of the Company’s Form 10-K for the year ended December 31, 2023 and Forms 10-Q for the quarters ended March 31, 2024 and June 30, 2024 and its performance of obligations under the LSA. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, risks related to the Company’s compliance with the LSA, including the risk that operating restrictions under the LSA adversely affect the Company’s ability to conduct its business, the risk that the Company will not achieve milestones required to access future tranches under the LSA, and the risk that the Company will fail to comply with covenants under the LSA, including with respect to required revenue levels, which could result in an event of default. Except as required by law, the Company undertakes no obligations to make any revisions to the forward-looking statements contained in this Current Report or to update them to reflect events or circumstances occurring after the date of this Current Report, whether as a result of new information, future developments or otherwise.




Item 9.01
Financial Statements and Exhibits.

(d)    Exhibits






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 11, 2024bluebird bio, Inc.
By:/s/ O. James Sterling
Name:O. James Sterling
Title:
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer


EX-10.1 2 ex-101lsaamend2.htm EX-10.1 Document

Exhibit 10.1
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of July 9, 2024 (the “Second Amendment Effective Date”), is entered into by and among BLUEBIRD BIO, INC., a Delaware corporation (“Company”), and each other Person that has delivered a Joinder Agreement from time to time party to the Existing Loan Agreement (together with Company, individually or collectively, as the context may require, “Borrower”), the several banks and other financial institutions or entities from time to time parties to the Existing Loan Agreement (each, a “Lender”, and collectively “Lenders”) that are party hereto and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and Lenders (in such capacities, including any successors or permitted assigns, “Agent”).
A.    Borrower, Lenders and Agent are parties to that certain Loan and Security Agreement, dated as of March 15, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time to date, the “Existing Loan Agreement” and the Existing Loan Agreement, as amended by this Amendment, the “Amended Loan Agreement”). Borrower, Lenders and Agent have agreed to certain amendments to the Existing Loan Agreement upon the terms and conditions more fully set forth herein.

SECTION 1Definitions; Interpretation.
(a)    Defined Terms. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Amended Loan Agreement.
(b)    Rules of Construction. The rules of construction that appear in Section 1.3 of the Amended Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.
SECTION 2Amendments to the Existing Loan Agreement.
(a)    The Existing Loan Agreement shall be amended as follows effective as of the date hereof (except as otherwise noted):
(i)    The following defined terms are hereby added, in appropriate alphabetical order, or amended and restated, as applicable, in Section 1.1 of the Existing Loan Agreement, as set forth below:
Second Amendment” means that certain Second Amendment to Loan and Security Agreement, dated as of the Second Amendment Effective Date by and among Borrower, Lenders and Agent.
Second Amendment Effective Date” means July 9, 2024.
(ii)    Section 7.1(a), Section 7.1(b) and Section 7.1(c) of the Existing Loan Agreement are hereby amended and restated to read as follows:
“(a)    as soon as practicable (and in any event within thirty (30) days or such longer period as may be agreed by Agent in its sole discretion) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if prepared) of Company and its Subsidiaries, including balance sheet and related statements of income, all certified by a duly authorized officer of Company to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year-end or quarter-end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements; provided that, with respect to the monthly financial statements for the months ending on March 31, 2024 through September 30, 2024, Borrower shall be in compliance with this clause (a) so long as the financial statements provided to Agent for such months shall be



in a form substantially similar to the example sent by Borrower to Agent after the Closing Date and prior to the First Amendment Effective Date;
(b)    as soon as practicable (and in any event (i) by August 31, 2024 for the fiscal quarter ended March 31, 2024, (ii) by September 30, 2024 for the fiscal quarter ended June 30, 2024 and (iii) within forty-five (45) days or, in each case of the foregoing clauses (i), (ii) and (iii), such longer period as may be agreed by Agent in its sole discretion) after the end of each of the first three fiscal quarters of each fiscal year, unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if prepared) of Company and its Subsidiaries, including balance sheet and related statements of income and cash flows accompanied by a report detailing any occurrence that could reasonably be expected to have a Material Adverse Effect (including the commencement of any material litigation by or against Borrower), certified by a duly authorized officer of Company to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments;
    (c)    as soon as practicable (and in any event (i) by August 31, 2024 for the fiscal year ended December 31, 2023 and (ii) ninety (90) days for each fiscal year thereafter, or in each case of the foregoing clauses (i) and (ii), such longer period as may be agreed by Agent in its sole discretion) after the end of each fiscal year, audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if prepared), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified without qualification (other than a “going concern” qualification as it relates to Borrower’s cash levels so long as no Event of Default has occurred or is continuing) by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied by any management report from such accountants (it being understood that Ernst & Young LLP and any other accounting firm of national standing are reasonably acceptable to Agent);”
(iii)    Section 7.20(a) of the Existing Loan Agreement is hereby amended and restated to read as follows:
“(a)    Borrower (i) shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respects with all applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations and it being agreed by the parties hereto that Borrower’s late delivery and filing of its Form 10-K for the fiscal year ended December 31, 2023 and its Form 10-Q for the fiscal quarter ended March 31, 2024 shall be deemed not to violate this Section 7.20(a) so long as such documents are filed by August 31, 2024 and that Borrower’s late delivery and filing of its Form 10-Q for the fiscal quarter ended June 30, 2024 shall be deemed not to violate this Section 7.20(a) so long as such document is filed by September 30, 2024), and (ii) shall, or cause its Subsidiaries to, obtain and maintain all material required Governmental Approvals reasonably necessary in connection with the conduct of Borrower’s business. Borrower shall not become an “investment company,” a company that would be an “investment company” except for the exclusion from the definition of “investment company” in Section 3(c) of the 1940 Act, or a company controlled by an “investment company” under the 1940 Act, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation X, T and U of the Federal Reserve Board of Governors).”
(b)    References Within Amended Loan Agreement. Each reference in the Amended Loan Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Amended Loan Agreement. This Amendment shall be a Loan Document. Any failure by Borrower to perform any obligation under this Amendment shall constitute an Event of Default under the Amended Loan Agreement.
    2


SECTION 3Conditions to Effectiveness. The effectiveness of this Amendment shall be subject to satisfaction of each of the following conditions precedent:
(a)    Agent shall have received this Amendment, executed by Agent, Required Lenders, and Borrower;
(b)    immediately after giving effect to this Amendment, the representations and warranties contained in Section 4 hereof shall be true and correct on and as of the Second Amendment Effective Date as though made on and as of such date; and
(c)    immediately after giving effect to this Amendment, there exist no Events of Default or events that, with the passage of time, could result in an Event of Default.
SECTION 4Representations and Warranties. To induce Agent and Lenders to enter into this Amendment, Borrower hereby confirms, as of the date hereof and immediately after giving effect to this Amendment, (a) that the representations and warranties made by it in Section 5 of the Amended Loan Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date); and (b) that there has not been and there does not exist a Material Adverse Effect.
SECTION 5Miscellaneous.
(a)    Loan Documents Otherwise Not Affected; Reaffirmation. Except as expressly amended pursuant hereto or referenced herein, the Existing Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. Lenders’ and Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future. Borrower hereby reaffirms the security interest granted pursuant to the Loan Documents and hereby reaffirms that such grant of security in the Collateral granted as of the Closing Date continues without novation and secures all Secured Obligations under the Amended Loan Agreement and the other Loan Documents. Borrower acknowledges and agrees that it does not have any defense, set-off, counterclaim or challenge against the payment of any sums owing under the Existing Loan Agreement and the other Loan Documents, or the enforcement of any of the terms or conditions thereof.
(b)    Conditions. For purposes of determining compliance with the conditions specified in Section 3 hereof, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the date hereof specifying its objection thereto.
(c)    Release. In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors and assigns, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or
    3


in relation to, or in any way in connection with the Existing Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto (collectively, the “Released Claims”). Borrower waives the provisions of California Civil Code section 1542, which states:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above. The provisions of this section shall survive payment in full of the Secured Obligations, full performance of all the terms of this Amendment and the other Loan Documents.
In addition to the release contained above, and not in limitation thereof, Borrower hereby agrees that it will never prosecute, nor voluntarily aid in the prosecution of, any action or proceeding relating to the Released Claims, whether by claim, counterclaim or otherwise. If, and to the extent that, any of the Released Claims are, for any reason whatsoever, not fully, finally and forever released and discharged pursuant to the terms above, Borrower hereby absolutely and unconditionally grants, sells, bargains, transfers, assigns and conveys to Agent all of the Released Claims and any proceeds, settlements and distributions relating thereto.
(d)    No Reliance. Borrower hereby acknowledges and confirms to Agent and Lenders that Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.
(e)    Binding Effect. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.
(f)    Governing Law. This Amendment and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.
(g)    Complete Agreement; Amendments. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.
(h)    Severability of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.
(i)    Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.
(j)    Electronic Execution of Certain Other Documents. The words “execution,” “execute”, “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this
    4


Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
(k)    Inconsistencies. To the extent of any inconsistency between the terms and conditions of this Amendment and the terms and conditions of the Existing Loan Agreement and the other Loan Documents, the terms and conditions of this Amendment shall prevail.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

    5


IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.
BORROWER:
BLUEBIRD BIO, INC.
Signature:    /s/ Andrew Obenshain        
Print Name:     Andrew Obenshain
Title:     Chief Executive Officer

[Signature Page to Second Amendment to Loan and Security Agreement]



AGENT:
HERCULES CAPITAL, INC.
Signature:    /s/ Seth H. Meyer            
Print Name:     Seth Meyer
Title:         Chief Financial Officer

LENDERS:
HERCULES CAPITAL, INC.
Signature:    /s/ Seth H. Meyer            
Print Name:     Seth Meyer
Title:         Chief Financial Officer

HERCULES PRIVATE CREDIT FUND 1 L.P.
By: Hercules Private Global Venture Growth Fund GP I LLC, its general partner
By: Hercules Partner Holdings LLC, its sole member
Signature:    /s/ Seth H. Meyer            
Print Name:     Seth Meyer
Title:         Authorized Signatory

HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.
By: Hercules Private Global Venture Growth Fund GP I LLC, its general partner
By: Hercules Partner Holdings LLC, its sole member
Signature:    /s/ Seth H. Meyer            
Print Name:     Seth Meyer
Title:         Authorized Signatory

[Signature Page to Second Amendment to Loan and Security Agreement]

EX-101.SCH 3 blue-20240709.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 blue-20240709_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 blue-20240709_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 09, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 09, 2024
Entity Registrant Name bluebird bio, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-35966
Entity Tax Identification Number 13-3680878
Entity Address, Address Line One 455 Grand Union Boulevard
Entity Address, City or Town Somerville
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02145
City Area Code 339
Local Phone Number 499-9300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BLUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001293971
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.bluebirdbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports blue-20240709.htm blue-20240709.xsd blue-20240709_lab.xml blue-20240709_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "blue-20240709.htm": { "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20240709", "dts": { "inline": { "local": [ "blue-20240709.htm" ] }, "schema": { "local": [ "blue-20240709.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "blue-20240709_lab.xml" ] }, "presentationLink": { "local": [ "blue-20240709_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.bluebirdbio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blue-20240709.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blue-20240709.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001293971-24-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-24-000022-xbrl.zip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end XML 16 blue-20240709_htm.xml IDEA: XBRL DOCUMENT 0001293971 2024-07-09 2024-07-09 0001293971 false 8-K 2024-07-09 bluebird bio, Inc. DE 001-35966 13-3680878 455 Grand Union Boulevard Somerville MA 02145 339 499-9300 false false false false Common Stock, $0.01 par value per share BLUE NASDAQ false